Empiric therapy of bacterial infections in patients with severe neutropenia

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 3, 1998, Pages 467-472

  Glauser, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G DERIVATIVE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CONFERENCE PAPER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION RISK; LEUKOCYTE COUNT; NEUTROPENIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; NEUTROPENIA; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 0031746493     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00038-8     Document Type: Conference Paper

References (22)

1. Bochud P.Y., Calandra T., Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med. 97:1994;256-264.
2. Bochud P.Y., Eggiman P., Calandra T., van Melle G., Saghafi L., Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: clinical spectrum and risk factors. Clin Infect Dis. 18:1994;25-31.
3. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 64:1966;328-340.
4. Browett P, Schwarer A, Whitby M, The Australian Cefpirome Study Group (1997) Comparison of cefpirome/gentamicin and piperacillin/gentamicin as empiric therapy for neutropenic fever (abstract). 20th ICC, Sydney, Australia.
5. Cometta A., Zinner S., de Bock R., Calandra T., Gaya H., Klastersky J., Langenaeken J., Paesmans M., Viscoli C., Glauser M.P. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 39:1995;445-452.
6. Cometta A., Calandra T., Gaya H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 40:1996;1108-1115.
7. Cordonnier C., Herbrecht R., Pico J.L., Gardembas M., Delmer A., Delain M., Moreau P., Ladeb S., Nalet V., Rollin C., Gres J.J. Cefepime/amikacin versus ceftazidime/amikacin as empiric therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group Clin Infect Dis. 24:1997;41-51.
8. Elting L.S., Bodey G.P., Keefe B.H. Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis. 14:1992;1201-1207.
9. Elting L.S., Khardori N., Bodey G.P., Fainstein V. Nosocomial infections caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 11:1990;134-138.
10. Ceftazidime combined with a short or long course of amikacin for empiric therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 317:1987;1692-1698.
11. Vancomycin added to empiric combination antibiotic therapy for fever in granulocytopenic patients. J Infect Dis. 163:1991;951-958.
12. Single daily dosing of amikacin and ceftriaxone is as efficacious and no more toxic than multiple daily dosing of amikacin and ceftazidime. Ann Intern Med. 119:1993;584-593.
13. Freifeld A.G., Walsh T., Marshall D., et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 13:1995;165-176.
14. Gerber L., Wing E.J. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin Infect Dis. 21:1995;1047-1048.
15. Hazel D.L., Graham J., Dickinson J.P., Newland A.C., Kelsey S.M. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. J Chemother. 9:1997;267-272.
16. Kelsey S.M., Weinhardt B., Pocock C.E., Shaw E., Newland A.C. Piperacillin/tazobactam plus gentamicin as empiric therapy for febrile neutropenic patients with haematological malignancy. J Chemother. 4:1992;281-285.
17. Kerr K.G., Hawkey P.M., Child J.A., Norfolk D.R., Anderson A.W. Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem. Postgrad Med J. 66:1990;1090.
18. Micozzi A., Nucci M., Vendetti M., Gentile G., Girmenia C., Meloni G., Martino P. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empiric treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis. 12:1993;1-8.
19. Pizzo P.A., Hathorn J.W., Hiemenz J., et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 315:1986;552-558.
20. Reiffers J, Cony MP, Pris J (1992) Efficacy of cefpirome in the initial empiric management of febrile neutropenic patients with hematologic malignancies (abstract). 32nd ICAAC, October 11, Anaheim, CA.
21. Ruiz-Irastorza G., Barreiro G., Aguirre C. Reversible bone marrow depression by high dose piperacillin/tazobactam. Br J Haematol. 95:1996;611-612.
22. Yamamura D., Gucalp R., Carlisle P., Cimino M., Roberts J., Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother. 41:1997;1704-1708.